The Newsroom
Research·October 22, 2026 at 6:21 AM EDT·1 source

Roche talks up Phase 3 success rate as it unveils pipeline cuts

NVS -3.3%AZN
NVS · last 30 trading days-1.8% since the news
News

What happened

  • Roche unveiled cuts to its drug-development pipeline.
  • CEO Thomas Schinecker highlighted Roche’s Phase 3 success rate.
  • The article contrasts Roche with Novartis, Novo and AstraZeneca, which faced late-stage clinical failures this summer.

Why it matters

Pipeline decisions and late-stage clinical performance are relevant to healthcare investors assessing Roche’s research productivity and portfolio risk.

Read more on YouBank

The Newsroom, ranked for your desk

About ninety free sources every ten minutes, one story per event, read for you: bankers, investors, operators and students each get their own desk. Free to start.

Who is involved

Roche talks up Phase 3 success rate as it unveils pipeline cutsRocheNovartisNVSNovoAstraZenecaAZNThomas Schinecker
CompanyPerson

Sources (1)

  1. Endpoints NewsOct 22
    Roche talks up Phase 3 success rate as it unveils pipeline cuts

Related

Read more on YouBank

The Newsroom, ranked for your desk

About ninety free sources every ten minutes, one story per event, read for you: bankers, investors, operators and students each get their own desk. Free to start.

  • Why it matters to youEvery story matched to your watchlist, your contacts and your pipeline.
  • Follow developing storiesAn alert, and a push, the moment a story you follow moves.
  • Your briefing, read aloudA few minutes each morning with a chapter per story.
  • Brief modeSwipe through the day, a 20-second card each.